NASDAQ:VXRTVaxart Stock Price, Forecast & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 339.1% and is now trading at $9.09.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.06. Vaxart had a negative return on equity of 104.25% and a negative net margin of 281.50%.
View Vaxart's earnings history.

Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

3 brokers have issued 12-month price targets for Vaxart's stock. Their forecasts range from $6.00 to $22.00. On average, they expect Vaxart's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price.
View analysts' price targets for Vaxart.

News articles about VXRT stock have trended extremely negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Vaxart.

Vaxart saw a increase in short interest in June. As of June 30th, there was short interest totaling 6,770,000 shares, an increase of 65.5% from the June 15th total of 4,090,000 shares. Based on an average daily volume of 17,320,000 shares, the days-to-cover ratio is presently 0.4 days.
View Vaxart's Short Interest.

Some companies that are related to Vaxart include Halozyme Therapeutics (HALO), Ablynx (ABLYF), Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO) and BAVARIAN NORDIC/S (BVNRY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Dynavax Technologies (DVAX), BioNano Genomics (BNGO), ADMA Biologics (ADMA), OrganiGram (OGI) and VBI Vaccines (VBIV).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by many different retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.37%), UBS Group AG (0.28%), Prudential Financial Inc. (0.27%), Hussman Strategic Advisors Inc. (0.18%), Bank of New York Mellon Corp (0.11%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

VXRT stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, and Todd C Davis.
View insider buying and selling activity for Vaxart.

VXRT stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Prudential Financial Inc., UBS Group AG, Bank of New York Mellon Corp, Russell Investments Group Ltd., National Asset Management Inc., Rathbone Brothers plc, and New York State Common Retirement Fund. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $9.09.

Vaxart has a market capitalization of $992.65 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]